equityflowunderstand the flow and follow it
EquityFlow › Companies › Dualyx

Dualyx

Biotech · Ghent, BE

Develops immune-modulation therapeutics targeting TNFR2 for autoimmune diseases

In the network

Shares the most investors with (number = shared investors):
Exciva 2

Funding history

DateRoundAmount
May 2023Series A
Belgian biotech Dualyx raised a 40m EUR Series A co-led by Fountain Healthcare Partners, Forbion and Andera Partners to advance its DT-001 autoimmune programme.
$43M

Investors

Tap an investor to see what else they have backed.

Andera PartnersForbionFountain Healthcare Partners

Other companies in Biotech

ImperagenHaga BiosciencePixelgen TechnologiesGallantChai DiscoverySNIPR BiomeCellbox LabsScope BiosciencesGenLuminaActitheraNUCLIDIUMAnocca

Other companies in BE

TurnUpCompanion.energySensieD-CRBNBorroEDGXKoios CareBizzyThe Hacking GamesCowboyBetterPicAxiles Bionics

Other companies at Series A stage

&Done&Open011h01Health1000 Satellites100ms11x.ai12 Pharmacy180° Seguros1X Technologies1k Kirana Bazaar207
Explore funding flow on EquityFlow →

Data is community-curated and may be incomplete.